A-listers provide a $50M B round to AstraZeneca’s antibiotics spinout Entasis

John Carroll

Last summer, AstraZeneca formally spun out its pared-down early-stage unit in Waltham, MA, as Therapeutics, bequeathing a $ 40 million A for a launch after it failed to find a buyer for the group. Today, the company gained another $ 50 million in venture backing from some A-list investors.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS